An update from Biomerica ( (BMRA) ) is now available.
On April 16, 2025, Biomerica announced a 1-for-8 reverse stock split effective April 21, 2025, to increase the bid price of its common stock and maintain its Nasdaq listing. This move will reduce the number of outstanding shares from approximately 20.4 million to 2.5 million, while the number of authorized shares remains unchanged. The reverse stock split aims to enhance Biomerica’s market position by ensuring compliance with Nasdaq’s minimum bid price requirements.
Spark’s Take on BMRA Stock
According to Spark, TipRanks’ AI Analyst, BMRA is a Neutral.
Biomerica’s stock score is primarily impacted by its financial struggles, including persistent losses and negative cash flows. The technical analysis provides mixed signals, with a hint of bullish momentum overshadowed by an overbought RSI. Valuation concerns, highlighted by a negative P/E ratio, further contribute to the low score.
To see Spark’s full report on BMRA stock, click here.
More about Biomerica
Biomerica, Inc. is a global biomedical technology company that develops, patents, manufactures, and markets advanced diagnostic and therapeutic products. These products are used at the point-of-care and in hospital/clinical laboratories for the detection and treatment of medical conditions, with a focus on gastrointestinal and inflammatory diseases.
YTD Price Performance: 89.67%
Average Trading Volume: 1,038,442
Technical Sentiment Signal: Buy
Current Market Cap: $10.14M
Learn more about BMRA stock on TipRanks’ Stock Analysis page.